Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses
Frontiers in Pharmacology · 12.09.2023 · 14
DOI: 10.3389/fphar.2023.1230783 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 12.09.2023. Verfasst von Xuan He und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Xindu District Shibantan Street Community Healthcare Center, Chengdu, China. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Resveratrol, a polyphenol found in various plants, is known for its diverse bioactivities and has been explored in relation to nonalcoholic fatty liver disease (NAFLD). However, no high-quality evidence exists regarding its efficacy. Objective: a meta-analysis was conducted to evaluate the potential efficacy of resveratrol in treating nonalcoholic fatty liver disease by analyzing both preclinical studies and clinical trials.
Method
PubMed, Embase and Web of Science were searched for the included literature with the criteria for screening. Quantitative synthesis and meta-analyses were performed by STATA 16.0.
Results
Twenty-seven studies were included, and the results indicated that resveratrol effectively improved liver function, reduced fatty liver indicators, and affected other indices in preclinical studies. The effective dosage ranged from 50 mg/kg-200 mg/kg, administered over a period of 4–8 weeks. While there were inconsistencies between clinical trials and preclinical research, both study types revealed that resveratrol significantly reduced tumor necrosis factor-α levels, further supporting its protective effect against nonalcoholic fatty liver disease. Additionally, resveratrol alleviated nonalcoholic fatty liver disease primarily via AMPK/Sirt1 and anti-inflammatory signaling pathways.
Conclusion
Current meta-analysis could not consistently verify the efficacy of resveratrol in treating nonalcoholic fatty liver disease, but demonstrated the liver-protective effects on nonalcoholic fatty liver disease. The large-sample scale and single region RCTs were further needed to investigate the efficacy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Xindu District Shibantan Street Community Healthcare Center, Chengdu, China.
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
- Department of Gastroenterology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Zitieren
APA
He, X., Li, Y., Deng, X., Xiao, X., & Zeng, J. (2023). Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1230783
Vancouver
He X, Li Y, Deng X, Xiao X, Zeng J. Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1230783
BibTeX
@article{He2023,
author = {He, Xuan and Li, Yubing and Deng, Xinyu and Xiao, Xiaolin and Zeng, Jinhao},
title = {Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1230783}
}
EUVIMED